DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Delays in Neurological Drug Development in Japan


File Description SizeFormat
IntMed50_1565.pdf122.8 kBAdobe PDFView/Open

Title: Delays in Neurological Drug Development in Japan
Authors: Shimazawa, Rumiko / Ikeda, Masayuki
Issue Date: 1-Aug-2011
Publisher: The Japanese Society of Internal Medicine / 日本内科学会
Citation: Internal Medicine, 50(15), pp.1565-1568; 2011
Abstract: Objective The lag in the approval and development of neurological drugs between Japan and other countries has been a major issue for patients with neurological diseases. The objective of this study was to analyze the factors contributing to the delay in the launching of neurological drugs in Japan. Methods We analyzed data from Japan and the US for the approval of 36 standard neurological drugs and examined the potential factors that may cause the delay of their launch. Results Of the 36 standard neurological drugs, all of which were approved in the US, only 21 were introduced in Japan from June 1999 to April 2010, whereas the other 15, whose indications were Alzheimer disease, epilepsy, migraine, multiple sclerosis, and Parkinson disease, remained unapproved. The US led Japan in the number of introductions (20 versus 1), with introductions in Japan occurring at a median of 87 months after introductions in the US. Japan's review time of new drug applications (23 months) could not explain this lag. In 15 of the 21 approved drugs, the application data package included overseas data. The mean review time of these 15 drugs was significantly shorter than that of the other 6 drugs without overseas data. The maximum daily doses of 7 of the drugs were higher in the US than in Japan. Conclusion These results show that there is still a large gap between Japan and the US with regard to access to standard neurological drugs, despite several important reforms in the Japanese drug approval system.
Keywords: Clinical trials / Drug approval / Food and drug administration / International conference on har-monisation of technical requirements for registration of pharmaceuticals for human use (ICH)
URI: http://hdl.handle.net/10069/25855
ISSN: 09182918
DOI: 10.2169/internalmedicine.50.5061
Rights: Copyright (c) 2011 by The Japanese Society of Internal Medicine
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/25855

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace